Ovarian cancer is the most lethal gynecologic malignancy worldwide. 1 In most patients, ovarian carcinoma is diagnosed at an advanced stage and is treated with cytoreductive surgery and adjuvant platinum-based chemotherapy. Nearly 80% of patients respond to this treatment, but about half will recur and eventually acquire a chemoresistant phenotype. Once recurrent, epithelial ovarian cancer is generally considered incurable, and the average life expectancy is approximately 6 months after the documentation of platinum resistance. Understanding and targeting the molecular underpinnings of recurrent disease and the mechanisms of chemoresistance remain a challenge in cancer research. 2 In ovarian cancer, resistance to chemotherapeutics has been thoroughly studied. A number of mechanisms represent potential novel chemotherapeutic agents. Many chemotherapeutic agents induce apoptosis in tumor cells. Apoptosis may be targeted directly via activation or indirectly by lowering the threshold for its initiation by cytotoxic drugs. 3 Analysis of genome-wide DNA copy number changes in primary ovarian serous carcinoma 2 has identified a frequently amplified region of chr19p13.12, which harbors Notch3. 4 In contrast to other coamplified genes, Notch3 mRNA is most significantly upregulated in tumors with amplification. Notch3 (mRNA as well as protein) was overexpressed in more than 50% of high-grade tumors compared with the normal ovarian surface epithelium.
This study examined the clinical significance of Notch3 expression and assessed its usefulness as a potential therapeutic target in
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The Notch signaling pathway is evolutionarily conserved and includes ligands (δ and jagged), Notch receptors, and transcription factors. Notch is a transmembrane heterodimeric receptor, with 4 distinct members (Notch1 to Notch4) present in humans. In cancers, molecular genetic alterations, such as chromosomal translocation, point mutations, and chromosomal amplification at the Notch receptor loci, are the known mechanisms for the constitutive activation of the Notch pathway. Notch signaling activation has been demonstrated in the context of ovarian, breast, and lung cancers. 5.6 In animal models, constitutively active Notch4 expression induces mammary tumors in mice, 7 and Notch1-activating mutations contribute to the development of T-cell acute lymphoblastic leukemia. 8 Park et al 9 demonstrated that Notch3 expression is associated with postchemotherapy recurrence, probably as a result of upregulation of an adenosine triphosphate-dependent transporter gene, ABCB1, and several embryonic stem cell markers.
Taken together, these studies support an oncogenic role for Notch3. The current study investigated the relationship between Notch3 expression and tumor recurrence, and assessed the usefulness of Notch3 as a prognostic biomarker and therapeutic target in patients with advanced stage ovarian cancer.
Materials and Methods

Tissue Samples and Immunohistochemistry
Paraffin-embedded tumor tissue samples were obtained from the Department of Obstetrics and Gynecology at Shimane University Hospital (Izumo, Japan) and the Department of Obstetrics and Gynecology at Seirei Hamamatsu General Hospital (Hamamatsu, Japan). These included 61 samples with advanced stage (stage III, IV) ovarian carcinoma. Formalin-fixed, paraffin-embedded tissue samples of 61 ovarian cancers including 33 serous carcinomas, 3 mucinous carcinomas, 18 clear cell carcinomas, and 7 endometrioid carcinomas were used in this study. Diagnosis was based on conventional morphologic examination of sections stained with H&E. Tumors were classified according to the World Health Organization classification. Tumor staging was performed according to the International Federation of Gynecology and Obstetrics classification. The clinicopathologic characteristics of the patients included in this study are summarized in ❚Table 1❚. All patients were primarily treated with cytoreductive surgery and adjuvant conventional platinum and taxane chemotherapy (carboplatin AUC 5, paclitaxel 175 mg/m 2 , or docetaxel 70 mg/m 2 ). All of the cases received at least 6 cycles of chemotherapy. Acquisition of tissue specimens and clinical information was approved by an institutional review board (Shimane University and Seirei Hamamatsu General Hospital). The paraffin-embedded tissues were organized into tissue microarrays, which were made by removing 3-mm diameter cores of tumor from each block. The selection of the area to be cored was made by a gynecologic oncologist (K.N.) and pathology technician (K.I.) and was based on a review of the H&E-stained slides.
Immunohistochemistry
Formalin-fixed and paraffin-embedded sections were dewaxed in xylene and dehydrated in graded alcohol. The sections were heated in a microwave oven at 700 W for 10 minutes in ×1 antigen retrieval solution (Zymed, Invitrogen, Carlsbad, CA). Endogenous peroxidase was then blocked by immersing the sections in 0.3% hydrogen peroxide-methanol for 30 minutes. After antigen retrieval in a sodium citrate buffer, slides were incubated overnight at 4°C with a rabbit polyclonal Notch3 antibody (Santa Cruz Biotechnology, Santa Cruz, CA), at a dilution of 1:100. An EnVision+ System peroxidase kit (DAKO, Carpinteria, CA) was used for staining. For positive control, a uterine cervical carcinoma sample that we previously analyzed was used. 10 For negative control, isotype control immunoglobulin G was used. Slides for all samples were evaluated with a light microscope by 2 researchers (M.T.R. and K.N.), who were blind to the clinicopathologic factors. Because the distribution of Notch3 immunoreactivity was almost always homogeneous within a given tumor, we used intensity scores of 0 (undetectable), 1+ (weakly positive), or 2+ (strong positive) to evaluate Notch3 immunoreactivity. No statistically significant difference in scoring was found between observers. For discordant cases, a third investigator scored, and the final intensity score was determined by the majority scores. For the clinicopathologic and survival analysis, patients with no or weak expression were assigned to the low-expression group, and those with moderate or strong expression were assigned to the highexpression group.
Cell Culture and Cell Lines
Human ovarian serous carcinoma cell lines A2780 and MDAH2774 were obtained from the American Tissue Culture Center (Rockville, MD fetal bovine serum, 100 U/mL of penicillin, and 100 μg/mL of streptomycin.
Western Blot Analysis
Western blot analysis of the aforementioned ovarian carcinoma cell lines was performed. Similar amounts of total protein from each lysate were loaded and separated on 7.5% Tris-Glycine-SDS polyacrylamide gels (Novex, San Diego, CA) and electroblotted to Millipore Immobilon-P polyvinylidene difluoride membranes. The membranes were probed with the Notch3 antibody (1:100) followed by a peroxidase-conjugated antimouse or antirabbit immunoglobulin (1:10,000). All of the antibodies were purchased from Santa Cruz Biotechnology. The same membrane was probed with an antibody that reacted with glyceraldehyde 3-phosphate dehydrogenase for loading controls. Western blots were developed using chemiluminescence (Pierce, Rockford, IL).
Cell Proliferation and Apoptosis Assay
Cells were seeded in 96-well plates at a density of 3,000 per well. Two small interfering RNA sequences (siRNAs) that targeted Notch3 were designed, with sense sequences of GGGCAUGCAGGAUAGCAAGGAGAG and AGAUGGGACAUGUUCCAUAGCCUTG. Control siRNA (luciferase siRNA) was purchased from IDT (Coralville, IA). In addition, type 1 γ-secretase inhibitor was purchased from Calbiochem (San Diego, CA) and was dissolved in dimethyl sulfoxide (DMSO) as a 4-mmol/L stock solution. Cells were treated either with Notch3-specific siRNA oligofectamine (Invitrogen) or with a γ-secretase inhibitor with DMSO at a final concentration of less than 0.1%. After 4 days, the cell number was measured with MTT analysis using a microplate reader. Data were determined from 5 replicates and were expressed as the percentage of Notch3-specific siRNA vs control siRNA-treated cells or γ-secretase inhibitor-treated cells vs control DMSO-treated cells.
Bromodeoxyuridine (BrdUrd) uptake and staining were performed using a cell proliferation kit (Amersham, Buckinghamshire, England), and apoptotic cells were detected using an Annexin V staining kit (BioVision, Mountain View, CA). The percentages of BrdUrd-positive and Annexin V-positive cells were determined by counting approximately 400 cells from each well in 96-well plates. The data were expressed as the mean ± 1 standard deviation (SD) of triplicates.
Statistical Methods for Clinical Correlation
Progression-free and overall survival rates were calculated from the date of diagnosis to the date of first relapse or last follow-up. Age and performance status distributions were similar between patients expressing Notch3 and those not expressing it. The data were plotted as Kaplan-Meier curves, and the statistical significance was determined using the Log-rank test. Data were censored when patients were lost to follow-up. Student t test (for comparison of 2 groups) or one-way analysis of variance (for comparison of more than 2 groups) were used to evaluate numeric data.
Results
Overexpression of Notch3 Intracellular Domain (NICD3) in Advanced Stage Ovarian Carcinoma
We focused on the immunostaining intensity of NICD3 in the nuclei, because NICD3 has been established as a surrogate marker for Notch pathway activation.
In this study, we focused on advanced stage (stage III, IV) ovarian carcinomas because they were the most common. Sixty-one patients with stage III, IV primary ovarian carcinoma underwent primary cytoreductive surgery that was followed by a standard platinum and taxane chemotherapy regimen. Cytoreduction was optimal in 16 patients (residual tumor <1 cm) and suboptimal in 45 (residual tumor ≥1 cm). All of the cases were judged to be in clinical remission after adjuvant conventional chemotherapy. Primary surgical tissues were used for Notch3 protein immunohistochemistry. Nuclear staining of NICD3 was observed in some ovarian carcinoma cells ❚Image 1A❚ and ❚Image 1B❚. Overexpression of NICD3 (nuclear Notch3 immunointensity 2+ and 3+) was observed in 27.8% (17/61) of the analyzed tumors. Table 1 summarizes the relationship between clinicopathologic findings and overexpression of NICD3 in ovarian carcinomas. No significant associations were found between NICD3 overexpression and age, histologic subtype, or status of the residual tumor (Table 1) .
Relationship Between Clinicopathologic Findings and NICD3 Expression
NICD3 Overexpression Correlated With Shorter Progression-Free/Overall Survival in Patients With Stage III and IV Ovarian Carcinoma Treated With Platinum and Taxane Chemotherapy
Overexpression of NICD3 correlated with shorter progression-free survival in patients with advanced stage (stage III, IV) ovarian carcinoma treated with platinum and taxane chemotherapy. A total of 61 patients were diagnosed at stage III, IV, of whom 17 patients with NICD3 overexpression had a shorter progression-free survival than those without NICD3 expression (P < .05; log-rank test) ❚Figure 1A❚. Both residual tumor (≥1 cm) (P < .05; log-rank test) and overexpression of NICD3 (P < .05; log-rank test) correlated with shorter progression-free survival in a univariate analysis. The other clinicopathologic factors, including age, histologic subtype, and grade, did not influence progression-free and overall survival (data not shown). A significant correlation between overexpression of NICD3 and overall survival was also found in patients with stage III, IV ovarian carcinomas (P < .05; logrank test) ❚Figure 1B❚. Both residual tumor (≥1 cm) (P < .05; log-rank test) and overexpression of NICD3 (P < .05; log-rank test) also correlated with shorter overall survival in a univariate analysis. Other clinicopathologic factors such as age and histologic subtype did not influence progression-free and overall survival (data not shown).
Next, we focused on only those cases with positive residual tumor in advanced stage ovarian carcinoma and evaluated whether overexpression of NICD3 remained a biomarker for progression-free/overall survival in this series of patients. A total of 45 patients with stage III, IV ovarian carcinomas, all of whom underwent suboptimal primary cytoreduction followed by a standard platinum and taxane chemotherapy regimen, were included in the analysis. Among them, the 10 patients with NICD3 overexpression had a shorter progression-free/ overall survival than those without Notch3 NICD3 expression (P < .05; log-rank test) ❚Figure 1C❚ and ❚Figure 1D❚.
NICD3 Overexpression Was Observed in Recurrent Ovarian Cancer
Of 61 ovarian carcinomas used in this study, 5 represented matched primary and recurrent tumors pairs. Among these 5 patients, 3 showed increased NICD3 immunostaining intensity in recurrent tumors compared with the corresponding primary tumors, and 2 showed no difference in the recurrent tumor compared with the primary tumor ❚Table 2❚. Representative paired primary and recurrent ovarian serous carcinoma tissues are shown in ❚Image 1C❚ and ❚Image 1D❚. A B C C ❚Figure 1❚ Notch3 overexpression correlates with shorter progression-free survival in patients with stage III, IV ovarian carcinoma who received primary cytoreductive surgery, followed by a standard platinum and taxane chemotherapy regimen. A, B, Kaplan-Meier survival analysis showing that Notch3 overexpression (solid line, n = 17) is associated with a shorter progression-free/overall survival than weak or absent Notch3 expression in stage III or IV ovarian cancers (dashed line, n = 44) (P = .030, P = .016, respectively, log-rank test). C, D, Kaplan-Meier survival analysis showing that Notch3 overexpression (solid line, n = 10) is associated with a shorter progression-free/overall survival than weak or absent Notch3 expression in patients with stage III or IV ovarian cancer who underwent suboptimal primary cytoreduction followed by a standard platinum and taxane chemotherapy regimen (dashed line, n = 35) (P = .025, P = .018, respectively, log-rank test). 
Functional Analysis of Notch3 Expression
Western blot analysis of ovarian cancer cell lines using the Notch3 antibody demonstrated the expression of the 120-kDa NICD3 was higher in JHOC9, OVISE, and A2780 cell lines than in the other cell lines ❚Figure 2A❚.
To determine if Notch3 was essential for cell growth and survival in the cell lines that expressed it, we used either Notch3-specific siRNA or γ-secretase inhibitor 1. γ-secretase inhibitor 1 prevents the activation of Notch3 by inhibiting the proteolysis and translocation of the Notch3 cytoplasmic domain to the nucleus. This compound is a potent, specific inhibitor of the Notch pathway. 12, 13 Because γ-secretase inhibitor 1 is a nonspecific inhibitor of all Notch receptors, we also used Notch3-specific siRNA, which reduced the expression of Notch3 specifically via posttranscriptional silencing. Either the Notch3-specific siRNA or γ-secretase inhibitor (at a concentration of 1 µmol/L) was applied to the culture medium in 6 different ovarian cancer cell lines: JHOC5, JHOC9, OVISE, OV207, MDAH2770, and A2780. We found that there was a substantial reduction in the cell numbers of JHOC9, OVISE, and A2780 lines with high Notch3 expression compared with lines with negative or low Notch3 expression ❚Figure 2B❚ and ❚Figure 2C❚. OV207, which moderately expressed Notch3, was weakly affected by both Notch3 siRNA and the γ-secretase inhibitor.
NICD3 Expression Is Higher in Cisplatin-Resistant KFr13 Cells Than in Parental KF28 Cells
To test for its involvement in platinum resistance, Notch3 NICD3 expression was measured in platinum-resistant ovarian cancer cell lines. As previously reported, 10 KFr13 cells were derived from KF28 cells based on their resistance to cisplatin. The 50% inhibitory concentration (IC50) of cisplatin for KF28, KFr13, and KFr13Tx cells was 0.18, 0.85, and 0.53 μmol/L, respectively, indicating that the relative resistances of KFr13 and KFr13Tx cells to cisplatin were 4.7-and 2.9-times higher, respectively, compared with those of the parent line. Also, the IC50 of paclitaxel for KF28, KFr13, and KFr13Tx was 4.65, 2.61, and 12.70 μmol/L, respectively. This indicates that the relative resistance of KFr13Tx cells to paclitaxel is 5.0-fold compared with that of the corresponding parent line.
Interestingly, when NICD3 protein levels were examined with Western blot analysis, NICD3 expression was characteristically observed in cisplatin-resistant KFr13 cells, suggesting its involvement in cisplatin resistance ❚Figure 3A❚.
Suppression of NICD3 in the Cisplatin-Resistant Cell Line KFr13
The specific overexpression of NICD3 in cisplatinresistant lines suggests that this pathway may represent a target in cisplatin-resistant ovarian cancer. To determine 3B❚ and ❚Figure 3C❚. To assess the mechanisms underlying the growth inhibition by the Notch3 inhibitors in cell lines, we measured the percentage of BrdUrd-labeled cells for cellular proliferation, and Annexin V-labeled cells for apoptosis ❚Figure 3D❚. We found that both Notch3 inhibitors significantly reduced cellular proliferation and induced apoptosis in the cell lines with Notch3 overexpression compared with the controls (Figure 3D ).
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Suppression of NICD3 in Cisplatin-and PaclitaxelResistant Cell Lines KFr13Tx Cells
Platinum/taxane chemotherapy is the standard of care for first-line chemotherapy for epithelial ovarian cancer. Taxane resistance has been demonstrated in ovarian cancer. Therefore, we also assessed whether NICD3 represented a therapeutic target against both cisplatin and taxane resistance in ovarian cancer cells. KFr13Tx cells were established from overexpression of NICD3 was characteristically observed in both cisplatin-resistant KFr13 and cisplatin/paclitaxel-resistant KFr13Tx cells. NICD3 expression was upregulated in cisplatin-and cisplatin/paclitaxel-resistant ovarian cancer cells, therefore we assessed its usefulness as a therapeutic target. Selective downregulation of Notch3 using both Notch-specific siRNA and a γ-secretase inhibitor significantly reduced cellular proliferation and induced apoptosis of Notch3-expressing cells compared with controls. These observations are consistent with those of prior studies. Notch-specific siRNA and γ-secretase inhibitors have also been found to prevent Notch3 activation and to reduce proliferation in human ovarian, uterine cervical, and lung cancers 4, 5, 10 and in Kaposi sarcoma. 12 Given these promising anticancer effects, γ-secretase inhibitors may represent a novel therapeutic modality for patients with ovarian cancer who have chemoresistant tumors expressing Notch3.
These findings suggest that NICD3 is a critical driver of ovarian cancer cell growth and survival, which illustrates the paradigm of "oncogene addiction." 21 Cancer cells contain multiple genetic and epigenetic abnormalities. Despite this complexity, inactivation of a single oncogene is often sufficient to impair growth and survival. This phenomenon provides a rationale for molecular targeted therapy. 21 In light of this theory and our current findings, we propose that patients with ovarian cancer with NICD3 overexpression be considered for participation in clinical trials evaluating γ-secretase inhibitors either in the primary or recurrent setting.
In summary, we demonstrated that NICD3 was overexpressed in a subset of ovarian carcinomas. Of special interest was the finding that NICD3 expression was seen in recurrent ovarian cancers. NICD3 expression also was a prognostic factor for ovarian carcinomas in the current study. Therefore, NICD3 expression may represent a novel clinical parameter for the prediction of patient survival. Finally, our current observations have an important therapeutic implication. Detection of NICD3 expression in ovarian cancers may identify patients who may benefit from agents targeting the Notch signaling pathway. reduced cellular proliferation and induced apoptosis in the 2 cell lines with Notch3 overexpression compared with the controls (Figure 4 ).
Discussion
One of the critical challenges in the treatment of patients with ovarian cancer is the development of chemoresistant recurrent disease. Although the majority of patients initially respond to platinum-based chemotherapy, overall mortality has remained largely unchanged because most patients eventually succumb to recurrent platinum-resistant disease. Because the mechanism of recurrent disease is poorly understood, the development and selection of second-line therapeutic regimens for platinum-resistant disease remain largely empiric. 14 In this study, we assessed whether Notch3 pathway activation was related to tumor recurrence in clinical samples. We also assessed whether Notch3 expression differed between cisplatin-sensitive and -resistant ovarian cancer cells. Finally, we tested the Notch pathway as a potential therapeutic target.
Our most notable finding was that overexpression of NICD3 in primary ovarian cancer was highly predictive of a shorter progression-free interval. To date, there is no biomarker that predicts the risk of early tumor recurrence. Therefore, Notch3 expression may have the potential to be used alone or in combination with other markers as a new diagnostic tool to identify patients with ovarian cancer with a greater susceptibility to early recurrence. This is important because at least 60% of patients with advanced stage ovarian cancer who have no clinical evidence of disease after completing primary therapy ultimately experience a recurrence. 15 Recently, 2 different research groups reported findings similar to ours, showing that NICD3 expression intensity correlated with shorter progression-free/overall survival in ovarian cancer. 9, 16 Taken together, these observations may have an effect on clinical management. Patients with recurrent ovarian cancer derive the most benefit from secondary cytoreduction in the setting of an isolated platinum-sensitive recurrence. 15, [17] [18] [19] [20] Therefore, patients with NICD3-positive ovarian cancer may represent a subset in whom intensive follow-up may identify patients early enough to benefit from secondary cytoreduction.
Notch3 protein was expressed in a subset of ovarian cancer cell lines, and affected proliferation in these lines. Selective downregulation of Notch3 using both Notch-specific siRNA and a γ-secretase inhibitor significantly reduced cellular proliferation in vitro compared with controls. These observations are consistent with those of prior studies. 4, 20 Next, to elucidate the mechanisms underlying the effects of NICD3 in ovarian cancer recurrence, we measured NICD3 expression levels in cisplatin-and combined cisplatin/paclitaxel-resistant ovarian cancer cell lines. 11 Interestingly,
